# Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

> **NCT04428151** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 408 (actual)

## Conditions studied

- Squamous Cell Carcinoma of Head and Neck

## Interventions

- **DRUG:** Lenvatinib
- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Docetaxel
- **DRUG:** Capecitabine
- **DRUG:** Paclitaxel
- **DRUG:** Cetuximab
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT04428151
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-06
- **Primary completion:** 2024-05-31
- **Final completion:** 2025-10-30
- **Target enrollment:** 408 (ACTUAL)
- **Last updated:** 2025-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04428151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04428151, "Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04428151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*